Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €37.45 EUR
Change Today +0.50 / 1.35%
Volume 78.0K
As of 11:30 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

diasorin spa (DIA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/12/15 - €44.89
52 Week Low
10/13/14 - €27.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIASORIN SPA (DIA)

Related News

No related news articles were found.

diasorin spa (DIA) Related Businessweek News

No Related Businessweek News Found

diasorin spa (DIA) Details

DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages. Its immunodiagnostics instruments include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; ETI Max 3000, an automated microtiter plate analyzer; EVOlyzer 2-150/8 with disposable tips; and ELISA washers and readers. The company also offers molecular diagnostic products for oncology, hematology, and infectious diseases; systems, including LIAISON IXT and BULLET Pro to extract the nucleic acid from different samples types, as well as used for separation of cells; and LIAISON IAM to diagnose and monitor various infectious diseases and Onco-hematology parameters. It sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Founded in 1968

diasorin spa (DIA) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: €561.3K
Senior Corporate Vice President of Commercial...
Total Annual Compensation: €350.6K
Compensation as of Fiscal Year 2014.

diasorin spa (DIA) Key Developments

DiaSorin S.p.A. Reports Unaudited Consolidated Earnings Results for the Second Quarter and First Half Ended June 30, 2015

DiaSorin S.p.A. reported unaudited consolidated earnings results for the second quarter and first half ended June 30, 2015. For the quarter, the company reported sales and service revenues of EUR 127,500,000 against EUR 110,856,000 a year ago. EBIT was EUR 40,041,000 against EUR 32,040,000 a year ago. Profit before taxes was EUR 39,666,000 against EUR 31,963,000 a year ago. Net profit was EUR 26,208,000 against EUR 20,271,000 a year ago. EBITDA was EUR 48,317,000 against EUR 39,490,000 a year ago. Net cash from operating activities was EUR 21,469,000 against EUR 18,162,000 a year ago. For the first half, the company reported sales and service revenues of EUR 245,144,000 against EUR 216,771,000 a year ago. EBIT was EUR 75,077,000 against EUR 63,388,000 a year ago. Profit before taxes was EUR 73,837,000 against EUR 62,852,000 a year ago. Net profit was EUR 48,821,000 against EUR 39,973,000 a year ago. EBITDA was EUR 91,398,000 against EUR 78,077,000 a year ago. Net cash from operating activities was EUR 55,751,000 against EUR 52,870,000 a year ago. Free cash flow was EUR 39.3 million in the first semester 2015.

DiaSorin S.p.A., Board Meeting, Jul 30, 2015

DiaSorin S.p.A., Board Meeting, Jul 30, 2015. Agenda: To examine and approve the consolidated financial results for the first half of 2015.

DiaSorin S.p.A., H1 2015 Earnings Call, Jul 30, 2015

DiaSorin S.p.A., H1 2015 Earnings Call, Jul 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIA:IM €37.45 EUR +0.50

DIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $138.87 USD -0.31
BioMerieux €93.95 EUR +0.21
Cepheid $40.66 USD -2.68
ERBA Diagnostics Inc $1.99 USD -0.0006
Meridian Bioscience Inc $17.80 USD -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation DIA Industry Range
Price/Earnings 22.1x
Price/Sales 4.4x
Price/Book 3.9x
Price/Cash Flow 22.2x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIASORIN SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at